Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How do different GLP-1 mimetics differ in their actions?

Simeon Pierre Choukem, Jean-François Gautier

    Current Diabetes Reports
    |November 2, 2006
    PubMed
    Summary

    Glucagon-like peptide-1 (GLP-1) mimetics offer new type 2 diabetes treatments. GLP-1 receptor agonists aid weight loss, while DPP-IV inhibitors offer better tolerance, but their roles require further definition.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sustained Follow-up of Automated Insulin Delivery in a Real-World Setting: Results at 2 Years of the French Nationwide Observatory OB2F.

    Diabetes technology & therapeutics·2026
    Same author

    Insulin resistance and type 2 diabetes as allostatic responses to chronic nutrient excess.

    Cell metabolism·2026
    Same author

    Factors associated with prevalent hypertension among adults living with HIV receiving antiretroviral therapy in Yaounde, Cameroon: a cross-sectional study.

    AIDS research and therapy·2026
    Same author

    Tailored high-dose corticosteroids in patients with diabetes mellitus hospitalized with hypoxemic COVID-19 pneumonia: insights from the CocAA-CoLa Plus Study.

    Minerva medica·2026
    Same author

    Polymorphisms of the <i>plasmodium falciparum</i> dihydropteroate synthase gene among patients attending LEPI and ADLUCEM hospitals in the west region of Cameroon.

    Parasite epidemiology and control·2026
    Same author

    Oral health knowledge and practices of people living with type 2 diabetes in three health facilities in the Dschang Health District, West Region, Cameroon.

    The Pan African medical journal·2026

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Metabolic Diseases

    Background:

    • Type 2 diabetes involves complex pathophysiologic mechanisms.
    • Glucagon-like peptide-1 (GLP-1) has limitations for therapeutic use.
    • Novel GLP-1 mimetics aim to improve treatment efficacy and delivery.

    Purpose of the Study:

    • To review the mechanisms and clinical effects of GLP-1 mimetics.
    • To compare GLP-1 receptor agonists and dipeptidyl peptidase IV inhibitors.
    • To discuss the potential role of these agents in type 2 diabetes management.

    Main Methods:

    • Review of existing literature on GLP-1 mimetics.
    • Analysis of pharmacokinetic properties and clinical outcomes.
    • Comparative assessment of different GLP-1 targeting drug classes.

    Main Results:

    • GLP-1 mimetics target key type 2 diabetes mechanisms.
    • GLP-1 receptor agonists demonstrate significant weight loss effects.
    • Dipeptidyl peptidase IV inhibitors show a favorable tolerance profile.

    Conclusions:

    • GLP-1 mimetics present promising therapeutic options for type 2 diabetes.
    • The distinct profiles of GLP-1 receptor agonists and DPP-IV inhibitors offer tailored treatment possibilities.
    • Further research is needed to define the optimal place of GLP-1 mimetics in the evolving therapeutic landscape for type 2 diabetes.

    Related Experiment Videos